甲状腺功能亢进症:病因学、发病机制、诊断、管理、并发症和预后
甲状腺功能亢进症全球患病率为0.2%-1.3%,诊断需生化检查确认并明确病因。Graves病甲亢(70%)首选抗甲状腺药物治疗,但12-18个月疗程后约50%复发;长期治疗5-10年复发率15%。毒性结节性甲状腺肿多采用放射性碘或甲状腺切除术。预后可能通过快速持续控制甲亢改善。
要点
- 甲亢诊断需生化检查确认(TSH降低、FT4或FT3升高),并明确病因。
- Graves病甲亢首选抗甲状腺药物治疗,12-18个月疗程后约50%复发。
- 长期抗甲状腺药物治疗(5-10年)复发率15%,低于短期治疗。
核心结论
- 甲亢与死亡率增加相关,快速且持续地控制甲亢可能改善预后。
- Graves病甲亢首选抗甲状腺药物治疗,但12-18个月疗程后约50%复发。
- 长期抗甲状腺药物治疗(5-10年)可行,且复发率(15%)低于短期治疗(12-18个月)。
- 针对B细胞或TSH受体的创新疗法有望用于Graves病。
研究设计与样本
- 本文为综述,涵盖甲亢的病因学、发病机制、诊断、管理、并发症和预后。
主要发现
- 甲亢全球患病率为0.2%-1.3%。
- Graves病甲亢占70%,毒性结节性甲状腺肿占16%,亚急性肉芽肿性甲状腺炎占3%,药物(如胺碘酮、酪氨酸激酶抑制剂、免疫检查点抑制剂)占9%。
- 抗甲状腺药物治疗前年龄小于40岁、FT4浓度≥40 pmol/L、TSH结合抑制免疫球蛋白>6 U/L、甲状腺肿大小≥WHO 2级,增加复发风险。
- 破坏性甲状腺毒症通常轻微且短暂,仅重症病例需使用类固醇。
关键数值与推荐
- 临床怀疑甲亢时,应通过生化检查确认(如TSH降低、游离甲状腺素[FT4]升高或游离三碘甲状腺原氨酸[FT3]升高)。
- 生化检查确认甲亢后,应进行病因学诊断以明确致病疾病。
- TSH受体抗体、甲状腺过氧化物酶抗体、甲状腺超声和闪烁显像是有用的工具。
- Graves病甲亢首选抗甲状腺药物治疗。
- 毒性结节性甲状腺肿主要采用放射性碘(131I)或甲状腺切除术治疗,很少采用射频消融。
临床怎么用
- 临床怀疑甲亢时,应通过生化检查确认,并进行病因学诊断。
- Graves病甲亢首选抗甲状腺药物治疗。
- 毒性结节性甲状腺肿主要采用放射性碘(131I)或甲状腺切除术治疗,很少采用射频消融。
- 破坏性甲状腺毒症通常轻微且短暂,仅重症病例需使用类固醇。
- 需特别关注妊娠、COVID-19或伴有其他并发症(如心房颤动、甲状腺毒性周期性麻痹和甲状腺危象)的甲亢患者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hyperthyroidism is a common condition with a global prevalence of 0·2-1·3%. When clinical suspicion of hyperthyroidism arises, it should be confirmed by biochemical tests (eg, low TSH, high free thyroxine [FT4], or high free tri-iodothyonine [FT3]). If hyperthyroidism is confirmed by biochemical tests, a nosological diagnosis should be done to find out which disease is causing the hyperthyroidism. Helpful tools are TSH-receptor antibodies, thyroid peroxidase antibodies, thyroid ultrasonography, and scintigraphy. Hyperthyroidism is mostly caused by Graves' hyperthyroidism (70%) or toxic nodular goitre (16%). Hyperthyroidism can also be caused by subacute granulomatous thyroiditis (3%) and drugs (9%) such as amiodarone, tyrosine kinase inhibitors, and immune checkpoint inhibitors. Disease-specific recommendations are given. Currently, Graves' hyperthyroidism is preferably treated with antithyroid drugs. However, recurrence of hyperthyroidism after a 12-18 month course of antithyroid drugs occurs in approximately 50% of patients. Being younger than 40 years, having FT4 concentrations that are 40 pmol/L or higher, having TSH-binding inhibitory immunoglobulins that are higher than 6 U/L, and having a goitre size that is equivalent to or larger than WHO grade 2 before the start of treatment with antithyroid drugs increase risk of recurrence. Long-term treatment with antithyroid drugs (ie, 5-10 years of treatment) is feasible and associated with fewer recurrences (15%) than short-term treatment (ie, 12-18 months of treatment). Toxic nodular goitre is mostly treated with radioiodine (131I) or thyroidectomy and is rarely treated with radiofrequency ablation. Destructive thyrotoxicosis is usually mild and transient, requiring steroids only in severe cases. Specific attention is given to patients with hyperthyroidism who are pregnant, have COVID-19, or have other complications (eg, atrial fibrillation, thyrotoxic periodic paralysis, and thyroid storm). Hyperthyroidism is associated with increased mortality. Prognosis might be improved by rapid and sustained control of hyperthyroidism. Innovative new treatments are expected for Graves' disease, by targeting B cells or TSH receptors.
引用
- Wiersinga WM, Poppe KG, Effraimidis G, et al. Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis. Lancet Diabetes Endocrinol. 2023. PMID: 36848916. doi:10.1016/S2213-8587(23)00005-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。